Karyopharm Therapeutics Enters Restructuring Agreement With Lenders, Clearing Path For A Merger With Ayrmid; Secures Commitments For Up To $55M Of Debtor-In-Possession Financing
During this process, Karyopharm remains focused on its commitment to advancing its multiple myeloma and myelofibrosis programs and improving the lives of the patients Karyopharm serves and will continue to operate in
Karyopharm made a deal with lenders to restructure its debt. The company can now merge with Ayrmid and get money to keep going.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.